10-K: Haemonetics Reports FY2026 Results, Navigates Market Shifts

Haemonetics Corporation's fiscal year 2026 annual report details a 2.0% decrease in net revenues to $1.33 billion, impacted by portfolio transitions, while the Hospital segment showed growth.

Summary

• Haemonetics Corporation reported net revenues of $1.334 billion for fiscal year 2026, a 2.0% decrease compared to fiscal year 2025.
• The decrease in revenue was primarily attributed to portfolio transitions in the Plasma and Blood Center segments, including the customer transition of CSL Plasma and the divestiture of the Whole Blood product line, which together represented approximately $153 million in fiscal 2025 revenue.
• The Hospital segment, however, saw a 4.3% increase in revenue, driven by growth in Hemostasis Management and Transfusion Management product lines.
• Operating income decreased by 29.3% to $156.7 million, largely due to an impairment of intangible assets related to Attune Medical, partially offset by pricing benefits and reduced restructuring costs.
• The company acquired Vivasure Medical Limited for $164.4 million, expanding its Hospital business unit's presence in interventional cardiology.
• Haemonetics repaid its 2026 Notes at maturity for $300 million and had $245.4 million in cash and cash equivalents as of March 28, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the reported decrease in net revenues and operating income, largely driven by portfolio adjustments and asset impairments, despite positive developments in the Hospital segment and strategic acquisitions.

Positives

• Hospital segment revenue increased by 4.3% to $588.3 million, driven by strong performance in Hemostasis Management and Transfusion Management.
• Gross profit increased by 5.2% to $787.6 million, with gross margin improving to 59.0% from 55.0% in the prior year, reflecting a shift towards higher-margin products and innovation.
• The company successfully acquired Vivasure Medical Limited, strengthening its position in the interventional cardiology market.
• Research and development expenses decreased by 4.7%, partly due to lower costs associated with EU MDR and EU IVDR compliance.
• The company maintained compliance with its credit facility covenants.

Negatives

• Net revenues decreased by 2.0% to $1.334 billion, primarily due to portfolio transitions in the Plasma and Blood Center segments.
• Operating income decreased by 29.3% to $156.7 million, significantly impacted by an $86.5 million impairment of intangible assets related to Attune Medical.
• Selling, general, and administrative expenses increased by 1.3% due to acquisition costs, tariffs, and higher performance-based compensation.
• The Blood Center segment revenue decreased by 15.3% due to the divestiture of the Whole Blood product line.
• The effective tax rate increased to 24.0% from 20.9% in the prior year.

Risks

• Material reductions in purchasing from or loss of a significant customer could adversely affect the business, with one Plasma customer accounting for 13% of total net revenues in fiscal 2026.
• Intense competition in the medical device market and the rapid pace of technological change could adversely affect the business.
• Defects or quality issues associated with products could lead to recalls, safety alerts, lost sales, and reputational damage.
• Cybersecurity threats and data breaches pose a risk to operations and sensitive information.
• The company is subject to extensive government regulation, and non-compliance could adversely affect financial condition and results of operations.
• Changes in tax laws or exposure to additional income tax liabilities could materially impact financial condition and results of operations.
• The company has a significant amount of debt, which may decrease business flexibility and increase borrowing costs.
• International operations are subject to geopolitical events, economic volatility, and varying regulatory environments.
• The company's intellectual property may be subject to misappropriation in some countries.
• Product liability claims and other litigation could adversely affect financial condition, results of operations, or liquidity.
• Climate change and measures to address it could adversely affect business operations and supply chains.
• Actual or threatened public health crises could harm the business.

Future Outlook

The company's strategy focuses on driving long-term value through its Plasma and Hospital segments, which are believed to have the greatest growth potential. The Blood Center segment is being managed with a focus on targeted opportunities in plasma and platelets.

Management Comments

• We believe that Plasma and Hospital have the greatest growth potential and are well positioned to drive long-term value.
• Blood Center operates in more challenging markets, and we have sharpened our focus accordingly on targeted opportunities – particularly in plasma and platelets – while ensuring continued alignment of this business with the Company’s broader strategic objectives.
• Our investment in research and development is critical to driving our future growth.

Industry Context

StockSavvy.ai notes that Haemonetics operates in the competitive medical technology sector, with key segments including plasma collection, blood center solutions, and hospital-based interventional and blood management technologies. The company faces competition from major players like Terumo BCT, Fresenius SE & Co. KGaA, and Abbott Laboratories.

Comparison to Industry Standards

• Haemonetics' Plasma segment competes with Fresenius Fenwal Aurora and Aurora Xi devices, and Terumo BCT's Rika device, focusing on procedure duration, donor experience, plasma yield, product quality, reliability, ease of use, and long-term cost-effectiveness.
• In the Blood Center market, Haemonetics' MCS brand apheresis equipment competes with products from Terumo BCT and Fresenius, with technology, speed, quality, reliability, and ease of use being key differentiators.
• For Vascular Closure, Haemonetics' VASCADE and PerQseal products compete with offerings from Terumo BCT, Abbott Laboratories, Cordis, and Teleflex, emphasizing clinical and economic value, ease of use, and workflow improvements.
• In Sensor-Guided Technologies, Haemonetics' OptoWire and SavvyWire compete with Abbott Laboratories, Boston Scientific, and Philips in the coronary physiology market, with SavvyWire facing potential competition from SoloPace for LV pacing during TAVR procedures.
• The ensoETM system for Esophageal Protection competes with temperature monitoring and other esophageal protection devices, while also facing competition from Pulse Field Ablation (PFA) technologies.
• For Hemostasis Management, Haemonetics' TEG analyzer competes with routine coagulation tests and other viscoelastic testing systems like ROTEM and VerifyNow from Werfen, and HemoSonics Quantra.
• In Cell Salvage, Haemonetics' Cell Saver Elite+ competes with products from LivaNova PLC, Medtronic, and Fresenius, with competition based on reliability, ease of use, service, support, and price.
• Transfusion Management products, SafeTrace Tx and BloodTrack, compete with standalone BBIS systems like WellSky and SSC Soft, as well as EHR software with integrated solutions from Cerner and Clinsys.

Legal Proceedings

• Haemonetics is involved in patent litigation concerning its plasma collection patents against Terumo BCT and Fresenius Kabi USA LLC.
• A lawsuit was filed by Knoninklijke Philips N.V. and IP2IPO Innovations, Ltd. alleging infringement of a patent by OpSens's interventional cardiology systems, which has been settled.
• A putative class action lawsuit was filed against Haemonetics regarding alleged violations of the Illinois Biometric Information Privacy Act (BIPA) related to its eQue donor management software, which has been settled.

Stakeholder Impact

• Shareholders may see continued volatility in stock price due to market conditions and the company's share repurchase program.
• Employees are subject to ongoing training and performance management, with a focus on talent attraction and retention.
• Customers in the Plasma segment may experience changes due to the transition of CSL Plasma.
• Hospitals may see benefits from new product offerings in the Hospital segment, such as Vivasure's PerQseal Elite.

Next Steps

• Continue to invest in technology to lower the overall cost to collect plasma while maintaining high standards of quality and safety.
• Pursue further regulatory clearances for additional enhancements to the overall product offering in the Plasma segment.
• Focus on targeted opportunities in the Blood Center segment, particularly in plasma and platelets.
• Continue to expand the Vascular Closure portfolio into the large bore market with PerQseal Elite.
• Monitor the impact of global macroeconomic conditions, including inflation, tariffs, interest rates, monetary policy, exchange rates, and geopolitical developments.

Key Dates

Recommendation

While Haemonetics shows resilience in its Hospital segment and has made strategic acquisitions, the overall decline in revenue and significant impairment charges warrant a cautious approach. The company's ability to navigate market shifts and integrate acquisitions effectively will be key to future performance. Investors should monitor the impact of ongoing portfolio rationalization and competitive pressures.

Keywords

Haemonetics Corporation, SEC Filing, 10-K, Annual Report, Medical Technology, Plasma Collection, Blood Center, Hospital Technologies, Vascular Closure, Hemostasis Management, Financial Results, Acquisition, Vivasure Medical